Clinical evidence shows that AposHealth (an FDA-cleared medical device) improves pain, stiffness, and function in people with knee osteoarthritis.
However, it’s uncertain if these improvements are clinically meaningful. The analyses suggest that AposHealth is cost saving by £1,958 per person when compared with standard care if knee surgery is delayed for 5 years. Because the evidence for the potential cost savings is limited, further data collection is recommended to understand if cost savings are made once AposHealth is used in the NHS.
Recent Posts
NICE Approves Ruxolitinib Cream for Treating Vitiligo with Facial Involvement
NICE Backs Ruxolitinib Cream Vitiligo Treatment
Ruxolitinib cream vitiligo therapy has received a major endorsement from the National Institute for Health and Care Excellence (NICE), which recommends it for non-segmental vitiligo with...
Economic Impact of Industry Clinical Trials in Europe
Industry clinical trials in are a vital engine of medical innovation and economic growth, with the European Economic Area (EEA) generating €35.7 billion in Gross Value Added (GVA) in 2025 from these activities. This includes €21.7 billion from direct, indirect, and induced effects, €3.6 billion f...
Merck Portfolio Optimization: Strategic Reorganization for Enhanced Commercial Execution
Merck's portfolio optimization strategy includes reorganizing its Human Health division into two focused business units—Oncology and Specialty, Pharma & Infectious Diseases—to sharpen commercial execution across its growing pipeline. This